SCHEMBL6450381

SCHEMBL6450381

CCOC(=O)/C=C/C(F)(F)c1ccc(-c2ccc(OC)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 1/20 0.43
ALDH1A1 P00352 3/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
GAA P10253 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
KMT2A Q03164 2/20 0.41
POLB P06746 1/20 0.41
CYP1A1 P04798 1/20 0.40
CYP1B1 Q16678 1/20 0.40
MAOB P27338 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.39
CES2 O00748 1/20 0.39
ACHE P22303 1/20 0.39
CES1 P23141 1/20 0.39
HPGD P15428 2/20 0.39
MAPT P10636 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6450384 1.00 MLYCD (0.43) MLYCDALDH1A1NPC1RAB9AGAA
SCHEMBL7062432 0.84 HCAR2 (0.47) ALDH1A1NPC1RAB9AL3MBTL1KMT2A
SCHEMBL7062429 0.84 HCAR2 (0.47) ALDH1A1NPC1RAB9AL3MBTL1KMT2A
SCHEMBL6462011 0.83 MAOB (0.41) ALDH1A1CYP1A1CYP1B1MAOBPTGDR2
SCHEMBL6462008 0.83 MAOB (0.41) ALDH1A1CYP1A1CYP1B1MAOBPTGDR2
SCHEMBL19511062 0.81 LMNA (0.43) MLYCDALDH1A1KMT2ACES2ACHE
SCHEMBL2003283 0.80 MAPT (0.48) MLYCDALDH1A1NPC1RAB9AL3MBTL1
SCHEMBL2003282 0.80 MAPT (0.48) MLYCDALDH1A1NPC1RAB9AL3MBTL1
SCHEMBL6454587 0.76 ALDH1A1 (0.52) ALDH1A1NPC1RAB9AGAAL3MBTL1
SCHEMBL15248923 0.76 CA12 (0.65) L3MBTL1KMT2AMAOBMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6852751-B2 Difluorobutyric acid metalloprotease inhibitors THE PROCTER & GAMBLE COMPANY (US) 2005-02-08 US disclosed
US-20030139453-A1 Difluorobutyric acid metalloprotease inhibitors THE PROCTER & GAMBLE COMPANY 2003-07-24 US disclosed
EP-1265865-A2 DIFLUOROBUTYRIC ACID DERIVATIVES AND THEIR USE AS METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2002-12-18 EP disclosed
WO-2001070693-A2 DIFLUOROBUTYRIC ACID DERIVATIVES AND THEIR USE AS METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2001-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139453-A1 Difluorobutyric acid metalloprotease inhibitors DPEP1, TMPRSS15, FAP MLYCD 1861/4885ALDH1A1 251/4885NPC1 1376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.